Transparency 10. Director General and offer services.
At present day, Cristina Avendaño Sola acts as a Director of the Spanish Agency of Drugs and Health Products, thanks to an appointment agreement the 23th of August of 2006, approved by the Subsecretary of Health and Consumption in replacement of María del Val Diez.
This appointment hasn’t been published in B.O.E., as it is legally perceptive for cabinet positions of such rank and nature, and that leads to the ignorance of which merits or contenders contest have been done to justify this designation.
During 1990 and 1995, Cristina Avendaño acted as technical adviser of the Subdirection of the Evaluation of Drugs of the General Direction of Pharmacy and Health Products in activities related to clinical tests for the authorization of drugs.
From year 2000, she is the person in charge of the Service and Unity of the Pharmacological Investigation of that hospital, positioned to consultancy and execution of clinical tests with drugs.
In the attached document, it can be checked that the present General Director of the Spanish Agency of Drugs appears referenced herself as the person who did the project “Scientific, technical and regulatory consultancy in clinical development of drugs for human usage”.
Cristina Avendaño Solá
Address: Universidad Autónoma de Madrid. c/ Arzobispo Morcillo
Web Page: www.cph.es
Present Professional Situation:
Organization: Universidad Autónoma de Madrid (UAM)
Center: Hospital puerta de hierro
Department: Pharmacology Service
Name: Cristina Avendaño Group
Director: Cristina Avendaño Solá
Components: Cristina Avendaño Solá
Investigation Lines and Technological Development
Title: Human pharmacology Studies and clinical tests
CNAE Code: 85.1 Health Activities
Unesco Code: 32 Health Science 3201 Clinical Science
Investigation Projects Done:
Collective agreement between the Spanish Agency of Drugs and the UAM in clinical evaluation of drugs. Clinical evaluation of new drug registers and elaboration of a Clinical Investigation Guide.
Scientific, technical and regulatory consultancy in clinical development for human drug usage.
CNAE Code: 24 Chemical Industry 24.4 Pharmaceutical Product Manufacture 85.1 Health Activities
Therefore, despite not being a directly related topic with veterinarian medicine, the fact of organically depend of the Subdirection of Drugs for Veterinarian Use, of the General Direction of the Spanish Agency of Drugs, we can conclude that this IS a matter related to the veterinarian sector.
Thus, from Veterinaria Digital, we want to expose the following facts:
1.The present director of the Spanish Agency of Drugs is practicing her post without existing a perceptive appointment published in the Boletín Oficial del Estado Español.
2.Remembering that this exactly same situation (absence of appointment publication) was already condemned by Veterinaria Digital with reference to Margarita Arboix as Subdirector of Drugs for Veterinarian Use of the Spanish Agency of Drugs.
Read post: Transparency (number 6, date 13th of September of 2010)
3.The present director of the Spanish Agency of Drugs appears as the reference person for companies which need “Scientific, technical and regulatory consultancy in clinical development for human usage” in a Spanish university.
4.Paradoxically (avoiding the expression “as it happens”), that exactly situation or “modus operandi” (we mean occupying a official regulatory position and offering consultancy to pass the regulatory stages) was reported by Veterinaria Digital with reference to Margarita Arboix as a Subdirector of Drugs for Veterinarian Uses of the Spanish Agency of Drugs.
Read post: Transparency (number 7, date 28th of September of 2010 and number 9, date 26th of October of 2010).
As a result, from Veterinaria Digital we must ask ourselves:
1.Why is people designated for public offices in the Department of Health, General Director of the Spanish Agency of Drugs and General Subdirector of Drugs for Veterinarian Use, without the public perceptive within the official channels (we mean the corresponding publication in B.O.E.)?
2.Should the Department appoint and keep up public offices to people that are simultaneously linked with universities that offer consultancy services in such topics that are related to the same position she holds in the civil service and whose connections with it might be considered, at least, incompatible?
3.Is it casual that after the dismiss, not published, of the subdirector of drugs, an appointment of the general director of the same organization, not published, offering consultancy in regulatory topics connected with her position?
4.Does it exist any relation between the number of studies entrusted to that universities (managed by the subdirector and general director of drugs) and the number of expedients approved in the Spanish Agency of Drugs both human and veterinarian medicine sectors?
5.How much have they collected within this “lobbies” and where have this benefits gone?